Drug Profile
Nanatinostat/valganciclovir combination therapy - Viracta Therapeutics
Alternative Names: CHR-3996; Nana-val; Tractinostat; Tractinostat-Viracta-Therapeutics; Valganciclovir/Nanatinostat combination therapy - Viracta Therapeutics; VRx-3996Latest Information Update: 13 Mar 2024
Price :
$50
*
At a glance
- Originator Chroma Therapeutics
- Developer Chroma Therapeutics; Viracta Therapeutics
- Class Amides; Antineoplastics; Antivirals; Hypoxanthines; Pyrimidines; Quinolines; Small molecules
- Mechanism of Action Cytomegalovirus replication inhibitors; DNA-directed DNA polymerase inhibitors; Histone deacetylase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Lymphoma
- Phase I/II Multiple myeloma; Nasopharyngeal cancer; Solid tumours
- Phase I Cancer
- No development reported Gastric cancer; Post-transplant lymphoproliferative disorder
Most Recent Events
- 08 Mar 2024 Viracta Therapeutics plans a phase I trial for Cancer (Late-stage disease, Second-line therapy or greater) in Spain (PO, Tablets) (NCT06302140)
- 01 Mar 2024 Phase-I clinical trials in Cancer (Late-stage disease, Second-line therapy or greater) in Spain (PO) (NCT06302140)
- 29 Feb 2024 Viracta Therapeutics completes enrolment in phase II trial in Lymphoma in Australia, Brazil, Canada, France, Germany, Hong Kong, Israel, Italy, Malaysia, Singapore, South Korea, Spain, Taiwan, United Kingdom and USA (PO) (NCT05011058)